Ortho Regenerative Technologies said its chief scientific officer, Michael Buschmann, has been appointed as bioengineering chair, professor and eminent scholar (an award from Virginia’s Center for Innovative...

Vital Therapies (NASDAQ:VTL) appointed Faheem Hasnain as chairman, effective immediately.

Ortho Regenerative Technologies appointed François-Xavier Lacasse to the newly created position of VP of product development. Dr. Lacasse’s mandate will be development and execution of a comprehensive product...

Zymeworks (NYSE:ZYME; TSX:ZYME) appointed Dr. Natalie Sacks, who has served as CMO of Aduro Biotech since Sept. 2016, to its board.

Microbix Biosystems (TSX:MBX) has appointed Cameron Groome as its president and CEO, with Vaughn Embro-Pantalony retiring from those positions but remaining an executive director, working closely with Mr. Groome to...

James Antonopoulos has joined Roth Capital Partners as managing director, co-head of healthcare investment banking.

Cantor Fitzgerald expanded its healthcare equity research team with the additions of Louise Chen and Travis Steed. Ms. Chen is joining Cantor as a senior research analyst and managing director, focused on specialty...

Oxford Immunotec Global (NASDAQ:OXFD) has appointed Karen Koski as head of strategy and investor relations, a newly created position that will report directly to CEO, Peter Wrighton-Smith. The appointment is effective...

Ladenburg Thalmann initiated coverage of Catalyst Biosciences (NASDAQ:CBIO) with a ‘buy” rating and $11.00 price target. The stock closed at $4.17 on June 5.

Closely held Braeburn Pharmaceuticals appointed Michael Derkacz as president and CEO, succeeding Behshad Sheldon, who is stepping down from both posts and as a director, effective immediately, but will continue to serve...

Closely-held Roth Capital Partners named Eric Cheng as managing director, head of healthcare investment banking.

Duff & Phelps has added managing director Phil Smith and director Adam Stormoen to its healthcare M&A advisory practice in Minneapolis. Mr. Smith has more than 25 years of healthcare transaction experience as an...

3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) appointed Dr. Kevin Little, a leading biomedical scientist and corporate executive, as its new chief scientific officer, effective immediately.  

John Calcagnini has joined Stout Risius Ross as managing director in the investment banking group’s healthcare industry practice.

3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) has appointed Harry Glorikian to its business advisory board.

BioTime (NYSE MKT:BTX) has appointed Stephana Patton as general counsel, a newly created position. Reporting in her new role to Adi Mohanty, co-CEO, Dr. Patton will oversee all legal matters at the company.

Richard Glickman, founder and chairman of Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP), was named to the added post of CEO. The board also accepted the resignation of Charles Rowland as CEO and an executive member of...

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP) appointed Hugh Rogers to its board.

Kenneth Galbraith, an accomplished life sciences industry veteran, has been appointed a director of Profound Medical (TSX-V:PRN). Mr. Galbraith has over 25 years of experience as an executive, director, investor and...

Steven Plymale, president and COO of Profound Medical (TSX-V:PRN), has been appointed an independent director of XOR-Labs, a spinoff from Toronto General Hospital at University Health Network, the world's leading center...

John Chambers has joined H.C. Wainwright as president and head of investment banking. Mr. Chambers joins HCW from Roth Capital Partners where he was vice chairman and head of healthcare investment banking. In his 28...